Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Market Movers
TipRanks 50 Index
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans & Pricing
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
ARGX
Stock Latest News
Ratings
Argenx Se’s Vyvgart Gains Momentum with Successful Phase 3 Results and Market Expansion Potential
4d ago
ARGX
Premium
The Fly
Argenx price target raised to $808 from $795 at Jefferies
5d ago
ARGX
Premium
The Fly
Argenx price target raised to $820 from $750 at Piper Sandler
5d ago
ARGX
Premium
Ratings
Argenx’s Vyvgart Shows Promising Phase III Results, Expanding Market Potential for Seronegative gMG Patients
6d ago
ARGX
Premium
The Fly
Argenx rises 6.0%
6d ago
ARGX
Premium
The Fly
Figma initiated, Okta upgraded: Wall Street’s top analyst calls
6d ago
S
FN
Premium
Company Announcements
argenx Reports Positive Results from ADAPT SERON Study for VYVGART
6d ago
6K
ARGX
Premium
The Fly
Argenx announces ADAPT SERON study of Vyvgart met primary endpoint
6d ago
ARGX
Premium
The Fly
Argenx initiated with an Outperform at RBC Capital
7d ago
ARGX
Premium
The Fly
Argenx treatment of idiopathic inflammatory myopathy granted orphan designation
11d ago
ARGX
Premium
Company Announcements
Argenx’s Long-term Safety Study on Efgartigimod for Pediatric Myasthenia Gravis: Key Insights for Investors
16d ago
ARGX
Premium
Company Announcements
Argenx’s Promising CIDP Treatment: A Closer Look at the Efgartigimod PH20 SC Study
16d ago
ARGX
Premium
Company Announcements
Argenx’s Efgartigimod Study: A Potential Breakthrough for Lupus Nephritis
24d ago
ARGX
Premium
Company Announcements
Argenx’s Efgartigimod Study: A Potential Breakthrough for Lupus Nephritis
26d ago
ARGX
Premium
The Fly
Argenx price target raised to EUR 700 from EUR 680 at Barclays
27d ago
ARGX
Premium
The Fly
Argenx price target raised to EUR 730 from EUR 700 at JPMorgan
27d ago
ARGX
Premium
The Fly
Argenx price target raised to EUR 655 from EUR 550 at Deutsche Bank
27d ago
ARGX
Premium
Ratings
Argenx Se: Strong Buy Rating Backed by Robust Financial Performance and Strategic Advancements
1M ago
ARGX
Premium
The Fly
Argenx price target raised to $1,070 from $1,060 at Guggenheim
1M ago
ARGX
Premium
The Fly
Argenx price target raised to $796 from $715 at Scotiabank
1M ago
ARGX
Premium
The Fly
Argenx price target raised to $775 from $750 at Evercore ISI
1M ago
ARGX
Premium
The Fly
Argenx price target raised to $880 from $829 at BofA
1M ago
ARGX
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >
You need to enable JavaScript to run this app.
